Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World
- 9.4.2014 | 12:00 PM - 1:30 PM
-
Hogan Lovells
555 13th Street NW
Washington, DC 20004
In the wake of FTC v. Actavis and the European Commission's decisions against Lundbeck, J&J and Novartis, pharma patent settlement agreements remain an issue in the US and Europe. Among questions yet to be resolved is how co-promotion and co-marketing, and manufacturing arrangements that are part of patent settlement agreements should be analyzed by antitrust enforcers.
WilmerHale Partner Mark Ford will be a featured speaker on this panel.
